158 results on '"Starr, Jason S."'
Search Results
2. Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms
3. Contributors
4. Integrated genomic and transcriptomic characterization of neuroendocrine carcinomas for improved treatment decision-making.
5. A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer
6. Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma.
7. Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma
8. Neuroendocrine Carcinoma of the Anus and Rectum: Patient Characteristics and Treatment Options
9. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy
10. Assessment of hematological toxicity in patients with advanced neuroendocrine tumors and extensive/innumerable bone metastases undergoing lutetium-177 DOTATATE treatment.
11. Clinical outcomes and molecular characteristics of patients with pancreatic acinar cell carcinoma.
12. Understanding the increasing incidence of neuroendocrine tumors
13. A Unicorn Disease: The Large Duct Variant of Invasive Ductal Adenocarcinoma of the Pancreas
14. CYP2D6‐guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial.
15. Targeting Leukemia Inhibitory Factor in Pancreatic Adenocarcinoma
16. Efficacy of first line checkpoint inhibitors in combination with chemotherapy in high‐grade extrapulmonary metastatic neuroendocrine carcinomas
17. An Excellent Response of Microsatellite Instability-High Pancreatic Adenocarcinoma to Pembrolizumab Treatment: The Role of Circulating Tumor DNA Testing
18. Characterizing bone metastases and skeletal-related events in patients with well-differentiated neuroendocrine neoplasms utilizing Ga68-DOTATE PET.
19. Characterizing the genomic landscape of POLE/POLD1-mutated colorectal adenocarcinoma.
20. Guideline compliance and outcomes of genetic testing in pancreatic cancer patients.
21. Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review
22. 5-FU induced cardiotoxicity: case series and review of the literature
23. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience.
24. Proton Therapy With Concurrent Chemotherapy for Thoracic Esophageal Cancer: Toxicity, Disease Control, and Survival Outcomes
25. Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study
26. 41 - Esophageal and gastric cancer
27. 42 - Hepatobiliary carcinomas
28. Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management
29. A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: Interim results.
30. Feasibility of disease recurrence monitoring in liver post-transplantation for patients with hepatocellular carcinoma via personalized and tumor-informed ctDNA test.
31. SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).
32. Co-occurring alterations across molecular pathways in metastatic colorectal cancer (mCRC).
33. Using cell-free circulating tumor DNA (cfDNA) to identify guideline-relevant biomarkers for therapy selection in 14,000 patients (pts) with metastatic colorectal cancer (mCRC).
34. Responses to immune checkpoint inhibition among MSI-H pancreatic ductal adenocarcinoma: A multi-institutional case series.
35. Atypical Lung Carcinoid With EML4/ALK Fusion Detected With Circulating Tumor DNA
36. Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced gastrointestinal cancers (aGI).
37. A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors: Interim results.
38. A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC).
39. Genomic predictors of benefit from checkpoint inhibition in neuroendocrine carcinoma.
40. Does detection of microsatellite instability-high (MSI-H) by plasma-based testing predict tumor response to immunotherapy (IO) in patients with pancreatic cancer (PC)?
41. Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
42. Cell-Free Tumor DNA Dominant Clone Allele Frequency (DCAF) Is Associated With Poor Outcomes In Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy
43. Treatment Landscape of Advanced High-Grade Neuroendocrine Neoplasms.
44. Painful Eruptions in a Patient With Cholangiocarcinoma Treated With Fibroblast Growth Factor Receptor Inhibitor
45. Tumor-Informed Assessment of Molecular Residual Disease and Its Incorporation Into Practice for Patients With Early- and Advanced-Stage Colorectal Cancer (CRC-MRD Consortia)
46. Association of cell-free DNA dominant clone allele frequency with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy.
47. Circulating tumor DNA-based genomic profiling of small bowel adenocarcinoma.
48. Circulating cell free tumor DNA detection as a prognostic tool in advanced pancreatic cancer.
49. Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.
50. Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.